Compare TRNS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNS | CAPR |
|---|---|---|
| Founded | 1964 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 324.6M |
| IPO Year | N/A | N/A |
| Metric | TRNS | CAPR |
|---|---|---|
| Price | $56.17 | $26.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $108.67 | $37.75 |
| AVG Volume (30 Days) | 135.6K | ★ 5.8M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $302,584,000.00 | $11,130,509.00 |
| Revenue This Year | $20.17 | N/A |
| Revenue Next Year | $7.66 | $7,736.03 |
| P/E Ratio | $46.90 | ★ N/A |
| Revenue Growth | ★ 11.81 | N/A |
| 52 Week Low | $50.23 | $4.30 |
| 52 Week High | $111.45 | $40.37 |
| Indicator | TRNS | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 71.27 |
| Support Level | $50.23 | $4.30 |
| Resistance Level | $56.90 | $29.23 |
| Average True Range (ATR) | 2.94 | 3.27 |
| MACD | 0.87 | 1.66 |
| Stochastic Oscillator | 65.21 | 60.24 |
Transcat Inc is involved in providing calibration and laboratory instrument services and the distribution of test, measurement, and control instrumentation. The product and services portfolio of the company consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, and others. The firm has Service and Distribution operating segments. The company derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Extech, FLIR, Fluke, Keysight, Megger, and others.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.